Stopping Solifenacin
Solifenacin can be stopped abruptly without tapering, as there is no evidence requiring gradual dose reduction for this antimuscarinic medication. Unlike medications with significant withdrawal syndromes (such as benzodiazepines or antidepressants), antimuscarinics do not cause physical dependence requiring a taper schedule 1.
Discontinuation Method
- Stop immediately: Simply discontinue the medication at the current dose (5 mg or 10 mg daily)
- No tapering required: The FDA label and clinical guidelines contain no recommendations for gradual dose reduction 1
- Timing flexibility: Can be stopped at any point during treatment without special preparation
What Happens After Stopping
Symptom recurrence is the primary concern, not withdrawal effects:
- Overactive bladder symptoms (urgency, frequency, incontinence) will gradually return to baseline levels
- The medication has a long elimination half-life of 33-85 hours, meaning effects diminish gradually over several days 2
- Symptom return typically occurs within 1-2 weeks as drug levels decline
Post-Cessation Monitoring
Monitor for return of OAB symptoms rather than withdrawal effects:
- Track micturition frequency, urgency episodes, and incontinence over the first 2-4 weeks
- Use a bladder diary if considering whether to restart therapy
- Reassess at 2-4 weeks post-discontinuation to determine if alternative OAB management is needed 3
Important Caveats
Do not confuse with medications requiring tapers: The evidence provided includes tapering protocols for benzodiazepines 4 and antidepressants 5, 6, but these are irrelevant to solifenacin discontinuation. Antimuscarinics have a completely different pharmacologic profile without physical dependence mechanisms.
Anticholinergic effects resolve quickly: Side effects like dry mouth and constipation typically resolve within days of stopping, as the drug is cleared 1.
Consider why you're stopping: If discontinuing due to inadequate efficacy, the AUA/SUFU guidelines recommend reassessment and consideration of combination therapy or third-line treatments rather than simply stopping 3.